Amp Capital Investors LTD Neurocrine Biosciences Inc Transaction History

Amp Capital Investors LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$79.65 - $106.22 $1.44 Million - $1.92 Million	-18,032 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$86.18 - $99.03 $127,891 - $146,960	-1,484 Reduced 7.6%	18,032 $1.73 Million
Q2 2021 Aug 16, 2021	SELL	$89.43 - $102.27 $1.12 Million - $1.28 Million	-12,495 Reduced 39.03%	19,516 $1.9 Million
Q1 2021 May 17, 2021	BUY	$87.57 - $119.4 $1.06 Million - $1.44 Million	12,076 Added 60.58%	32,011 $3.1 Million
Q4 2020 Feb 12, 2021	BUY	$86.91 - $108.33 $31,461 - $39,215	362 Added 1.85%	19,935 $1.9 Million
Q3 2020 Nov 12, 2020	BUY	$96.16 - $135.15 $245,208 - $344,632	2,550 Added 14.98%	19,573 $1.91 Million
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $254,674 - $390,167	2,993 Added 21.33%	17,023 $2.14 Million
Q4 2019 Feb 13, 2020	BUY	$86.8 - $118.57 $1.22 Million - $1.66 Million	14,030 New	14,030 $1.5 Million

626

94M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.2B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Amp Capital Investors LTD, based on Form 13F filings with the SEC.

Stay updated on Amp Capital Investors LTD with notifications on news.